Thirty-two hematologic malignancies -nine with cytogenetically identified 12p abnormalities and 23 with whole or partial losses of chromosome 12 -were selected for fluorescence in situ hybridization (FISH) investigations of 12p. These analyses revealed structural 12p changes, such as translocations, deletions, insertions, inversions and amplification, in 20 cases. ETV6 rearrangements were detected in three acute leukemias. One acute undifferentiated leukemia had t(4;12)(q12;p13) as the sole anomaly. The second case, an acute myeloid leukemia (AML), displayed complex abnormalities involving, among others, chromosomes 9 and 12. The third case, also an AML, had an insertion of the distal part of ETV6 into chromosome arm 11q and into multiple ring chromosomes, which also contained chromosome 11 material, resulting in an amplification of a possible fusion gene. The fusion partners in these cases remain to be identified. Thirty-one additional breakpoints on 12p could be characterized in detail. The majority of these breaks were shown to result in interchromosomal rearrangements, possibly indicating the location of hitherto unrecognized genes of importance in the pathogenesis of hematologic malignancies. The FISH analyses disclosed terminal or interstitial 12p deletions in 18 cases. Seven myeloid malignancies showed deletions restricted to a region, including ETV6 and CDKN1B, which has been reported to be frequently lost in leukemias. In four cases, the deletions involved both these genes, whereas two AML displayed loss of CDKN1B but not ETV6, supporting previously reported findings indicating a region of deletion not including this gene. However, one myelodysplastic syndrome lacked one copy of ETV6 but not CDKN1B. Hence, we suggest a minimal region of deletion on 12p located between the ETV6 and CDKN1B genes.
Introduction
The short arm of chromosome 12 (12p) is frequently involved in translocations in hematologic malignancies. 1 It has recently been shown that several of these rearrangements result in a fusion of the ETV6 gene, mapping to 12p13, to different partners, ie ABL, CBFA2, EVI1, MDS1, MN1, PDGFRB and STL, in such morphologically and clinically disparate diseases as acute lymphoblastic and myeloid leukemias (ALL and AML, respectively), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, some translocations do not appear to affect ETV6, having mostly a more proximal breakpoint. 13, 14 Fluorescence in situ hybridization (FISH) investigations, primarily on cytogenetically wellcharacterized 12p abnormalities in hematologic malignancies, have shown that the seemingly balanced 12p translocations may be quite complex, often resulting in cryptic deletions. [13] [14] [15] [16] Cytogenetically identified deletions of 12p are also common in acute leukemias, 17 and FISH analyses have revealed that they frequently are interstitial. 13, 14, 18 Furthermore, molecular studies with markers for ETV6 and the closely located CDKN1B have disclosed loss of heterozygosity (LOH) in 20-30% of childhood ALL. [19] [20] [21] The minimally deleted segment, which excludes ETV6 in single cases -at least in myeloid malignancies -seems to be restricted to a small region including CDKN1B, 22 which encodes a cell cycle inhibitor. 23 Although this gene thus seems to be an attractive tumor suppressor candidate, the other allele is only rarely mutated. 24, 25 The complexity, and the frequently cryptic nature, of 12p abnormalities indicates that the involvement of this chromosome arm in hematologic malignancies is underestimated. Further characterization of 12p rearrangements is important; first because they may reveal new fusion genes involving ETV6 and consequently increase our understanding of its functional properties, and second because identification of new breakpoints may disclose previously unrecognized oncogenes. Furthermore, the obscurity regarding the deletions and the potential tumor suppressor gene(s) on 12p necessitates further studies of the minimal region(s) lost. Our group recently reported frequent changes of ETV6, CDKN1B and CCND2 in hematologic disorders with structural abnormalities of 12p, including translocations, deletions, additions of unknown material, and inversions. 13 In the present work, nine additional cases with such aberrations and 23 with whole or partial losses of chromosome 12 in complex karyotypes were analyzed by FISH using a set of probes covering 12p.
Materials and methods

Patients
Hematologic malignancies with either cytogenetically detectable 12p abnormalities (nine cases) or whole or partial losses of chromosome 12 in complex karyotypes (23 cases) were selected for FISH analyses. The karyotypes of the latter cases were incompletely characterized, ie included marker chromosomes or translocations and other abnormalities involving unrecognizable chromosomal material. The following disease subgroups were included: one acute leukemia (not specified), one undifferentiated acute leukemia (AUL), two ALL, 18 AML, seven MDS, one polycythemia vera, one non-Hodgkin lymphoma (NHL), and one plasma cell leukemia (Table 1) .
Cytogenetic studies
Bone marrow and/or peripheral blood cells were cultured and cytogenetically investigated in a standard manner. The clonality criteria and the description of karyotypes followed the recommendations of ISCN (1995) . 34 The cell pellets used had been stored for 0-18 years at −18°C in methanol:acetic acid fixative (3:1, v/v). 6 F/86 AML 82ෂ83,XX,−X,der(X)t(X;8)(q11;q11),del(1)(p11),der(1) Subclone with del(12)(q?) t(1;9)(q32;q12),add(3)(q11),del(3)(p14),der(3)t(3;5) (q21;q13),der(4;17)(q10;q10),−5,del(5)(q15q22)×2,add (7)(q32),i(7)(q10),−8,−8,del(8)(q22),−9,del(10)(q24)×2, del(11)(p13)×2,add(12)(p11),−13,?dup (13) ( Probes FISH hybridizations were performed with probes for the CCND2, PRB, ETV6, CDKN1B and KRAS2 genes, and the D12S1455, D12S770, D12S797, D12S178 and D12S87 loci (Table 2) . Furthermore, cosmids mapping to 12q13 and the YAC 2G11, covering the HMGIC gene located at 12q15, 43 were used to identify and to some extent characterize 12q abnormalities. ETV6 was analyzed both by the YACs 964C10 and 958B8, 18 and the cosmids c50F4, c163E7, c179A6 and c148B6. 39 The latter two cosmids contain the 5Ј-and 3Ј-ends of ETV6, respectively, facilitating the verification of a breakpoint within this gene. The involvement of chromosome 12 and chromosome arm 12p were investigated by painting probes (wcp12 and pcp12p, respectively). These probes as well as the other wcp-probes used for identification of partner chromosomes and centromere-specific (cen) probes are commercially available.
FISH analysis
The hybridization technique was a modification of that previously described. 22 After spreading, the slides were kept at 65°C overnight, followed by treatment with 10 g/ml porcine pepsin (Serva, Heidelberg, Germany) in 50 mM HCl, to increase the penetration of the probes to the target DNA. Biotinylated probes were detected with avidin-Cy3 (Amersham, Amersham Place, UK) at a concentration of 1 g/ml. Digoxigenin-labeled probes were visualized using one layer of sheep antidigoxigenin-fluorescein isothiocyanate (FITC; Boehringer Mannheim, Mannheim, Germany) and one layer of donkeyantisheep-FITC (The Binding Site, Birmingham, UK), both at a concentration of 5 g/ml. The hybridization signals were analyzed in an Axioskop microscope (Zeiss, Oberkochen, Germany) coupled to a CytoVision Ultra system (Applied Imaging, Sunderland, UK) using a cooled, charge-coupled device camera. 
Results
FISH analyses
Twenty-seven of the 32 cases showed translocations or deletions involving chromosome 12, of which 20 had breakpoints located on 12p. The original karyotype was apparently misinterpreted in one case (32) in that the FISH analysis could not detect loss of chromosome 12. Only four leukemias showed a complete loss of a chromosome 12, ie no chromosomes apart from the normal chromosomes 12 were positive for wcp12 or pcp12p. Three malignancies (cases 14, 17 and 25) displayed involvement of 12p, but the changes were not possible to characterize at a locus-specific level because of poor quality of the mitoses.
12p breakpoints (Figure 1) More than 40 breaks on 12p, 34 of which could be characterized in detail, were identified among the 20 cases with 12p involvement. Three cases (2, 3 and 5) displayed a breakpoint located within the ETV6 gene (see below). Twenty-two breaks on 12p were proximal to ETV6. Two cases (13 and 27) had breakpoints between the ETV6 and CDKN1B genes, both resulting in interstitial deletions of 12p. Nine breakpoints occurred between the CDKN1B and KRAS2 genes, of which four resulted in deletions and the remaining in interchromosomal rearrangements. In seven cases the breaks were between the proximal D12S87 locus and the KRAS2 gene. Four cases displayed a breakpoint proximal to the D12S87 locus, but were positive for pcp12p and/or cen12. Nine breakpoints were mapped distal to ETV6, six of which located between this gene and PRB.
12p amplification
In one AML-M2 (case 16) a region including CCND2 was strongly amplified (Figures 2 and 3d) . The amplicon did not contain the proximal PRB gene or the distal subtelomeric D12S1455 marker.
12p deletions (Figure 2) Unbalanced rearrangements with breaks on 12p resulted in deletions in 18 cases. Seven myeloid malignancies displayed 12p deletions restricted to a region previously reported to be commonly lost in leukemias, including ETV6 and CDKN1B.
In four cases (1, 12, 23 and 24) , the deletions involved both these genes (Figure 4a and e), whereas two AML (cases 5 and 13) displayed loss of CDKN1B but not ETV6 (Figures 3b, 4c and 4d), and one MDS (case 27) lacked one copy of ETV6 but not CDKN1B (Figure 4f ). The latter case was weakly positive for the YAC 964C10, but negative for the ETV6-specific cosmids (Table 2) , indicating a proximal break close to ETV6. Two cases (12 and 16) showed unbalanced rearrangements with breakpoints telomeric to CCND2, resulting in deletions of the chromosomal segment distal to this gene. Finally, seven cases showed more extensive terminal deletions, four of which included KRAS2 and distal sequences, and three cases were negative for all tested locus-specific probes on 12p.
ETV6 rearrangements
The results from the hybridizations indicated ETV6 rearrangements in one AUL and two AML (cases 2, 3 and 5). Hybridizations performed on samples from case 2, an AUL cytogenetically characterized by an apparently balanced t(4;12)(q12;p13), showed the breakpoint on 12p to be located within the ETV6 gene; the 3Ј-end cosmid was present on the der(12) whereas the 5Ј-end cosmid was present on the der(4).
Case 3 displayed a complex FISH pattern (Figures 3a and  4b) . The YACs covering the ETV6 gene hybridized to several chromosomes: a strong signal was detected on a cytogenetically normal chromosome 12; a weaker signal was seen on a marker which was positive for pcp12p; and diminutive signals were present on one to four differently sized ring chromosomes and on the q-arm of chromosome 11, close to the MLL gene. The ring chromosomes displayed an irregular pattern when hybridized with pcp12p and wcp12, but were clearly positive for wcp11 as well as for MLL (Figure 3a) . FISH performed with the ETV6-specific cosmids disclosed that the 5Ј-end, but not the 3Ј-end, of ETV6 was present on only the normal-looking chromosome 12, whereas the 3Ј-end of ETV6, but not the 5Ј-end, was present on both chromosome 11 and the rings. The larger rings displayed two or four positive signals for this cosmid, whereas the small rings showed one signal.
The genetic changes resulting in an ETV6 rearrangement in case 5 were also quite complex (Figure 4c) . Two markers -a larger submetacentric and a smaller acrocentric-like chromosome -were shown to contain only material from chromosomes 9 and 12. The smaller marker, which displayed a strongly enhanced signal when hybridized with a centromere 9-specific probe, was weakly positive for the YACs covering ETV6, despite negativity for pcp12p. Hybridizations with intragenic cosmids showed the 5Ј-end of the gene to be inserted into this marker, whereas the 3Ј-end was lost. Both arms of the larger marker chromosome contained 12p sequences; only the most distal probes were present at the end of the long arm, and the most proximal probe was present at the short arm (Figure 3b ). Hybridizations with a YAC cover-
Figure 1
Schematic picture summarizing the positions of the 12p breaks. To the left, an ideogram of chromosome arm 12p and the corresponding approximate locations of the investigated genes and loci. Breakpoints are denoted by triangles. The origin of the fused chromosomal fragments is as follows: light gray, 12p; dark gray, 12q; black, other chromosomes; white, interstitial deletion, paracentric inversion or other intra-chromosome arm rearrangements (ie the fused fragment is also derived from 12p), half triangle, distal breakpoint (ie the break does not result in a fusion). A light gray (top)/dark gray (bottom) triangle hence indicates that 12p sequences telomeric to the breakpoint are fused to 12q material.
ing the ABL gene did not suggest the breakpoints on chromosome 9 to be close to this gene.
Discussion
Samples from 32 hematologic malignancies -nine with cytogenetically detectable 12p abnormalities including translocations, deletions, additions of unknown material and inversions, and 23 with whole or partial losses of chromosome 12 in complex karyotypes -were selected for FISH investigation. The analyses revealed frequent cytogenetically unrecognized translocations, deletions, and, in one case, amplification involving 12p.
ETV6 was disrupted in three cases, indicating the possible formation of fusion genes. Hybridizations performed on case 2, which had a balanced t(4;12)(q12;p13) as the sole chromosomal abnormality, showed that the ETV6 5Ј-end and 3Ј-end cosmids were separated and located on the der(4) and der (12) , respectively. This case was diagnosed as an AUL in 1979, and hence neither immunophenotyping nor cytochemical stainings were performed. Recently, two other groups have reported ETV6 rearrangements in AML or AUL with this translocation. 45, 46 This subgroup has been associated with threelineage dysplasia, low myeloperoxidase activity and CD7 positivity, and an early stem cell origin has been suggested. 47 Our finding supports that ETV6 is rearranged in such cases. A second case with a possible ETV6 fusion was characterized by complex rearrangements involving chromosomes 9 and 12 (case 5, Figures 3b and 4c) . The FISH results of this AML suggest a double breakage and interstitial deletion of 12p, perhaps a paracentric inversion, followed by a translocation with chromosome 9. To date, only one fusion partner on chromosome 9, ABL, has been reported in ALL, AML and CML. [2] [3] [4] ABL has the opposite orientation to the centromere as compared to ETV6, and consequently, the formation of an ETV6/ABL fusion requires at least three chromosomal breakpoints. 4, 48 However, the breakpoint on chromosome 9 in the present case was located far from ABL. In fact, the results suggest that the fusion partner is located on 9p or proximal 9q. Molecular characterization of this case is in progress. In this context, it is noteworthy that Berger et al 49 very recently reported a T-ALL with t(9;12)(p23ෂ24;p13), which involved ETV6. The third case, also an AML, with a breakpoint located within ETV6 displayed similarly intricate genetic changes (case 3, Figure 4b ). FISH indicated the 3Ј-end, but not the 5Ј-end, of ETV6 to be present on one to four rings and inserted into chromosome arm 11q (Figure 3a) . The cytogenetically normal chromosome 12, on the other hand, was positive for the ETV6 5Ј-end, but not the 3Ј-end. Hence, at the FISH level, the 5Ј-and 3Ј-parts of ETV6 were separated, making the expression of the wild-type product improbable -perhaps in effect silencing this gene. Even more likely, the pathogenetically relevant effect of these changes may be a fusion,
Figure 2
Deletion and amplification map. To the left, an ideogram of chromosome arm 12p and the corresponding approximate locations of the investigated genes and loci. A dashed line indicates that the border of the deletion is not determined. Filled boxes indicate genomic amplifications -in dual colors if the amplified region is a fusion gene. located on chromosome 12, between the promotor region of ETV6 and its first exons, and a part of an unrecognized gene located closely on 12p, or derived from elsewhere in the genome and inserted into this chromosomal region. We have recently shown such a cryptic insertion, not detected by wcp but only by sequence-specific probes, resulting in an ETV6/ABL fusion in a CML. 4 Alternatively, the rings and chromosome 11 may harbor the relevant fusion, resulting in a transcript between the 5Ј-end of an unidentified partner and the 3Ј-end of ETV6. However, in all but one reported fusions involving the promiscuous ETV6, the 5Ј-end of this gene is fused to the 3Ј-end of the partner. The only exception is the t (12;22) , resulting in MN1/ETV6 fusion, reported in myeloid malignancies. 9 The involvement of chromosome 22 was excluded in the present AML, suggesting the possibility of a second fusion containing the 3Ј-end of ETV6 in hematologic disorders. The creation of the ring chromosomes, which presumably was a secondary event, obviously amplified the possible fusion at the genomic level, as indicated by hybridization with the cosmid covering the 3Ј-end of ETV6, revealing up to nine copies in the same cell. Such genomic amplifications of fusion genes have previously been reported, eg in rhabdomyosarcomas with double minute chromosomes and in transforming CML showing a duplication of the Ph-chromosome. 50 Rings are rare in leukemias, 50 but have been shown to contain amplified regions in other neoplasms, eg low-malignant mesenchymal tumors. 51 Ring chromosomes were present in four additional cases, one of which (case 27, Figure 4f ) contained 12p material. The structure of this ring was quite similar to the rings in case 3, albeit not identical. Both were positive for the YAC 964C10, covering ETV6, but this gene was apparently deleted in case 27, as the ring was negative for ETV6 intragenic cosmids. The ring chromosome was further positive for the YAC containing KRAS2 and centromeric sequences. As a consequence, ETV6, but not CDKN1B, was hemizygously deleted in this case.
Cytogenetic deletions involving 12p are common in hematologic diseases. 17 The present investigation further confirms this, because 22 out of 32 samples analyzed showed such a genetic imbalance. Deletions have particularly often been reported in childhood ALL, in which molecular analyses indicate LOH of a region including ETV6. [19] [20] [21] FISH investigations of bone marrows from childhood leukemias with t(12;21), resulting in ETV6/CBFA2 fusion, have shown a concomitant deletion of the other ETV6 allele in the great majority of cases. 52 However, point mutations of ETV6 are extremely rare in childhood ALL. 25 The importance of the deletions might be explained by the interference between the wild-type ETV6 and the fusion product. 53 Hence, it is reasonable to argue that the frequent 12p deletions in t(12;21) leukemias are secondary events, also shown by Romana et al, 54 rather than indicating ETV6 to be a classic tumor suppressor. However, all deletions involving 12p in hematologic malignancies cannot be explained this way, first because some cases show deletions without harboring ETV6 rearrangements, and, second, because some deletions do not include ETV6. We have recently reported two such AML, without cytogenetic evidence of 12p abnormalities, which showed genomic deletions FISH images. (a) Case 3: to the left, a metaphase showing the simultaneous hybridization with pcp12p (yellow signal) and c148B6 (a cosmid located at the 3Ј-end of ETV6, red), revealing this part of ETV6 to be absent on the pcp12p-positive marker and the cytogenetically normal chromosome 12 (red arrows). Multiple signals were present on chromosome 11 and on one to four ring chromosomes (white arrows). To the right, a partial karyotype showing the results of a hybridization with wcp11 (green) and c148B6 (red). (b) Case 5: hybridization with wcp12 (green) and pcp12p (red) showed two distinct regions of 12p in the marker (white arrow). A second marker (red arrow) was only positive for 12q, but subsequent FISH experiments disclosed the 5Ј-end of ETV6 to be inserted into this chromosome. (c) Case 13: CDKN1B (yellow) was absent on the der(12)t(12;17) (white arrow), which was identified by pcp12p (red). (d) Case 16: CCND2 (red) was highly amplified in a subclone; here visualized both in a metaphase and in an interphase cell (white arrows). Green signal is pcp12p. (e) Case 24: three chromosomes displayed rearrangements involving chromosome 12, detected by wcp12 (red) and pcp12p (yellow). A small marker (white arrow) and a Bchromosome (red arrow) were both positive for 12q, and the distal part of the der(1) was positive for 12p (green arrow). (f) Case 31: simultaneous hybridization with wcp8 (yellow), a YAC covering the proximal D12S87 locus (red), and cen12 (green), revealing the proximal locus to be present on both the metacentric marker (red arrow) and on the other der(12), shown here to be a der(12)t(8;12) (white arrow). of a region including CDKN1B. 22 These findings were strengthened by the detection of similar deletions in cases 5 and 13 ( Figures 3c, 4c and d) , indicating a critical region of deletion on 12p excluding ETV6. Another informative case (27, Figure 4f ) displayed a deletion including ETV6, but not CDKN1B. This case may seem to support the observations by Takeuchi et al, 21 who suggested two different regions of deletions on 12p: one including ETV6 and one including CDKN1B. However, their childhood ALL series most likely contained cases with t(12;21), making it probable that a substantial proportion of the ETV6 deletions were secondary to this translocation. We would therefore rather suggest that the critically minimally deleted region of 12p is located between ETV6 and CDKN1B.
FISH performed on an AML-M2 (case 16) displayed a strongly increased signal when hybridized with cosmids specific for CCND2 (Figure 3d ). This is, to our knowledge, the first reported amplification of CCND2 in a myeloid malignancy. Amplifications of this chromosomal region have previously been detected, albeit rarely, in NHL and childhood ALL. 13, 55, 56 The amplicon was quite large in the reported NHL, but in the present case it was smaller, because PRB was not co-amplified. CCND2 encodes cyclin D2, a positive regulator of the cell cycle, and has been reported to be overexpressed in a majority of B cell chronic lymphocytic leukemias and lymphoplasmacytic lymphomas. 57 All three cytogenetically characterized cases with CCND2 amplifications (two NHL and the present AML) displayed an add(12p), indicating that such amplifications in fact are detectable at the cytogenetic level -similar to CCND1 amplification in head and neck carcinomas and 12q amplification in benign mesenchymal tumors, which are cytogenetically evident as homogeneous staining regions. 50 Furthermore, the present case implies that CCND2 amplification is a secondary genetic event, probably of selective advantage to the leukemic clone, because the abnormality was present only in a subclone ( Table 1) .
The present investigation emphasizes the frequent involvement and striking complexity of 12p abnormalities in hematologic disorders, also in cases not showing obvious cytogenetic involvement of this region. The results may suggest a minimal region of deletion on 12p located between the ETV6 and CDKN1B genes. Furthermore, the presence of several recurrent breakpoints on 12p not including ETV6 possibly indicates the location of hitherto unrecognized genes of importance in the pathogenesis of hematologic malignancies.
